Agricultural Biotechnology Coordination Act
SB 2692, the Agricultural Biotechnology Coordination Act, would require the U.S. Department of Agriculture to create a new Office of Biotechnology Policy. The office would be tasked with giving biotechnology a higher priority within USDA and coordinating departmental policy and activities related to biotechnology, biomanufacturing, synthetic biology, and other emerging technologies. It would be led by a director who reports directly to the Secretary of Agriculture or a designee.
The office’s responsibilities would include coordinating USDA work on research and development, communication, extension, education, regulation and labeling, and commercialization, use, and trade. It would also assist other USDA offices and agencies with biotechnology-related duties and provide leadership for interagency coordination with EPA, FDA, and relevant federal and state agencies. The bill also directs the office to consult with biotechnology developers, academics, agricultural producers, and other affected entities.
As drafted, the bill would amend the Department of Agriculture Reorganization Act of 1994 by inserting a new section establishing the office and by making a conforming amendment to USDA’s general authorities so the Secretary can carry out the new section. In practical terms, it would not directly regulate farmers or companies by itself, but it would reorganize USDA’s internal structure and centralize biotechnology policy coordination within the department.
The available context shows no recorded votes or committee debate, so there is no documented floor or committee sentiment to assess. Based on the bill text alone, the measure appears administrative and coordination-focused rather than regulatory, suggesting a generally pro-biotechnology posture. Potential points of contention would likely center on whether a new USDA office is necessary, how much authority it should have over labeling and regulation, and how it might affect coordination with EPA, FDA, states, and industry stakeholders.
The bill would amend the Department of Agriculture Reorganization Act of 1994 to add a new Section 223 establishing an Office of Biotechnology Policy within USDA and to confirm the Secretary’s authority to carry out that section. It would affect USDA internal governance by creating a centralized office responsible for coordinating biotechnology-related policy, research, education, regulation and labeling, commercialization, and interagency coordination, but it would not itself create new substantive biotechnology standards for private parties.
No committee transcript or vote history is available, so there is no direct evidence of support or opposition in the record provided. The bill’s structure suggests a generally favorable view of biotechnology and a desire for more organized federal coordination, which may appeal to agricultural, research, and industry stakeholders. At the same time, the absence of debate means any concerns about bureaucracy, regulatory reach, or federal-state coordination are not documented in the materials provided.
The main likely points of contention are institutional and regulatory rather than ideological: whether USDA needs a dedicated biotechnology office, whether that office should influence labeling and regulation, and how it should coordinate with EPA, FDA, and state agencies. Stakeholders that may differ include biotechnology developers and agricultural producers, who may favor clearer coordination, versus critics who may worry about added bureaucracy, centralization of authority, or insufficient safeguards around emerging technologies such as synthetic biology.